Table 2 Univariate analysis of clinical and molecular variables
From: TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Variables | N | Median PFS (months) | P | Median OS (months) | P |
|---|---|---|---|---|---|
Age | |||||
≤35 years | 81 | 78 | 0.02 | 141.5 | 0.005 |
>35 years | 150 | 48 | 65.6 | ||
WHO Grade | |||||
Grade II | 163 | 84 | <0.001 | 122.5 | <0.001 |
Grade III | 68 | 19.6 | 24 | ||
Histology | |||||
Astrocytic | 162 | 47 | 0.006 | 59.1 | <0.001 |
Oligodendroglial | 21 | 108 | NR | ||
Oligoastrocytic | 48 | 108.4 | 120.6 | ||
TERT promoter mutation | |||||
Mutant | 65 | 108 | 0.103 | 126 | 0.037 |
Wild type | 166 | 48 | 67 | ||
IDH mutation | |||||
Mutant | 157 | 71 | <0.001 | 120 | <0.001 |
Wild-type | 74 | 20 | 24 | ||
1p/19q codeletion | |||||
Yes | 37 | NR | <0.001 | 142.1 | <0.001 |
No | 189 | 48 | 60 | ||
